Clinical Trials
250 trialsCheckCell-2
Intima Bioscience, Inc.
ARTIA-Lung
Varian, a Siemens Healthineers Company
EPIC
Therakos LLC
BIB 01
Institut Bergonié
EMPIRE
Institut Bergonié
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Sutro Biopharma, Inc.
TUXEDO-5
MedSIR
CH:II
Lady Davis Institute
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies
Memorial Sloan Kettering Cancer Center
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
M.D. Anderson Cancer Center
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
Wake Forest University Health Sciences
LUNGadenosine
Centre Hospitalier Universitaire de Nice
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
Pfizer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
University of Texas Southwestern Medical Center
POIMS
University of Kansas Medical Center
SBRT_LOV
Universitair Ziekenhuis Brussel
NAJSCR
Sun Yat-sen University
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
AMBER
ETOP IBCSG Partners Foundation
Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
M.D. Anderson Cancer Center
BOUNCE
ETOP IBCSG Partners Foundation
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
Roswell Park Cancer Institute
SPICE
University of Cologne
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Indiana University
HAITEN-ICI
VA Office of Research and Development
SCION
University of British Columbia
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
SWOG Cancer Research Network
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections
The Cleveland Clinic
Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
University of Pittsburgh
STRIDER
Maastricht University Medical Center
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
Hetian District People's Hospital
Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung
Ohio State University Comprehensive Cancer Center
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Mainline Biosciences, Inc.
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Advaxis, Inc.
CheckMate 79X
Bristol-Myers Squibb
NSCLC
SCRI Development Innovations, LLC
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
ELEGANT
Takeda
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Criterium, Inc.
MEANING-20
Takeda
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)